Neurocrine Biosciences, Inc. · NASDAQ:NBIX

Neurocrine Biosciences — Q4 2019 Earnings Presentation

26 slides from Neurocrine Biosciences's earnings presentation, Feb 4, 2020

  1. Slide 1: Advancing Life-Changing Discoveries in Neuroscience

    Advancing Life-Changing Discoveries in Neuroscience Q4 2019 / Year-End February 4, 2020 NASDAQ: NBIX neurocrine.com

  2. Slide 2: Safe Harbor Statement and Non-GAAP Financial Measures

    Safe Harbor Statement and Non-GAAP Financial Measures In addition to historical facts, this presentation contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements related to: our preliminary unaudited financial

  3. Slide 3: Neurocrine 2019 Q4 Highlights & 2020 Key Activities

    Neurocrine 2019 Q4 Highlights & 2020 Key Activities Q4 2019 Highlights 2020 Key Activities ▪ INGREZZA® (valbenazine) Net Product Sales: ▪ Continued Focus on INGREZZA Commercial – $238MM with 42,100 TRx in Q4 2019 Execution and “Talk About TD” Disease State – $753MM with 132,700 TRx in FY 2019 Awaren

  4. Slide 4: Diversified Portfolio with Multi-Stage Programs

    Diversified Portfolio with Multi-Stage Programs PROGRAM THERAPEUTIC AREA PHASE 1 PHASE 2 PHASE 3 NDA COMMERCIAL INGREZZA® (valbenazine)* Tardive Dyskinesia ORILISSA® (elagolix)† Endometriosis opicapone‡ Parkinson’s Disease elagolix† Uterine Fibroids crinecerfont valbenazine* Congenital Adrenal Hyper

  5. Slide 5: 2020: Expand Potential Indications and Advance Clinical Programs

    2020: Expand Potential Indications and Advance Clinical Programs 3 Approved Medicines in 4 Indications INGREZZA® (valbenazine) for Tardive Dyskinesia APPROVED ORILISSA® (elagolix) for Endometriosis* APPROVED Opicapone for Parkinson’s Disease April 26, 2020 PDUFA† Elagolix for Uterine Fibroids* Q2 20

  6. Slide 6: Financial Summary

    Financial Summary $ Millions, Except Non-GAAP EPS Item Q4 ’19 Q4 ’18 2019 2018 Revenue $244.1 $131.4 $788.1 $451.2 - INGREZZA Product Sales, Net 237.9 130.3 752.9 409.6 - Collaboration Revenue 6.2 1.1 35.2 41.6 Non-GAAP R&D Expense 47.9 29.9 164.2 119.6 Non-GAAP SG&A Expense 87.4 60.5 304.6 217.1 No

  7. Slide 7: 2020 GAAP and Non-GAAP Expense Guidance

    2020 GAAP and Non-GAAP Expense Guidance $ Millions 2020 Guidance Range Item 2019 Actuals Low High Combined GAAP R&D and SG&A Expenses $554 $740 $770 Combined Non-GAAP R&D and SG&A Expenses $469 $620 $650 Increase in 2020 operating expenses reflect: – Increased investment in R&D programs including th

  8. Slide 8: Our Medicines Our Patients

    BIOSCIENCES Our Medicines Our Patients

  9. Slide 9: 1st FDA-approved Treatment for Adults with Tardive Dyskinesia (TD) – Launched in 2017

    1st FDA-approved Treatment for Adults with Tardive Dyskinesia (TD) – Launched in 2017 Most-Prescribed and Most-Preferred TD Therapy ▪ Rapid Improvement in Involuntary Movements ▪ Generally Well Tolerated ▪ Ease-of-Use: One Capsule, Once daily J.P.2019 Q4 Morgan Earnings Healthcare Presentation Confe

  10. Slide 10: Tardive Dyskinesia (TD): An Overview

    Tardive Dyskinesia (TD): An Overview TD is caused by TD is a movement prolonged use of disorder characterized by uncontrollable, abnormal 1 in 5 antipsychotics, commonly prescribed to treat schizophrenia, and repetitive movements U.S. adults live with a bipolar disorder & of the face, torso and/or m

  11. Slide 11: INGREZZA Continues to Exceed Expectations

    INGREZZA Continues to Exceed Expectations INGREZZA Net INGREZZA NetSales Salesand ~TRx and ~TRx $250 $238 50,000 Approximate TRx (in Thousands) Net Product Sales ($ in Millions) $198 $200 42.1K 40,000 $181 34.8K $150 $130 $136 31.6K 30,000 $111 $97 24.2K $100 22.9K 20,000 $71 19.4K 16.7K $50 12.5K 1

  12. Slide 12: Valbenazine: Chorea in Huntington Disease

    Valbenazine: Chorea in Huntington Disease Phase III Study to Treat Chorea in Adult Patients with Huntington Disease Chorea in Huntington Disease (HD) Valbenazine* An involuntary movement disorder estimated ▪ Targeted symptom control of chorea movements to affect approximately 90% of the 30,000 HD as

  13. Slide 13: 1st FDA-Approved Oral Treatment for Women with Moderate-to-Severe Endometriosis Pain

    Neurocrine Biosciences discovered and developed through Phase II; AbbVie received FDA approval and responsible for commercialization 1st FDA-Approved Oral Treatment for Women with Moderate-to-Severe Endometriosis Pain in Over a Decade - Launched in 2018 ▪ Less Estrogen = Less Painful Endometriosis L

  14. Slide 14: Elagolix: Potential Expanded Indications in Women's Health

    Elagolix*: Potential Expanded Indications in Women’s Health Uterine Fibroids Polycystic Ovary Syndrome NDA Submitted with PDUFA in Q2 2020 Phase II Study Ongoing Most 7 million common Most common women with symptomatic pelvic growth uterine fibroids hormonal affecting disorder 3.5 million 70 - 80% 2

  15. Slide 15: Opicapone for Parkinson's Disease

    Opicapone* for Parkinson’s Disease Target PDUFA Date of April 26, 2020 Parkinson’s Disease (PD) Opicapone† 1 million people impacted in the U.S. ▪ Novel COMT inhibitor as adjunctive therapy to levodopa/carbidopa in patients with Parkinson’s disease experiencing OFF episodes 2 out of 3 patients are o

  16. Slide 16: Crinecerfont: Classic Congenital Adrenal Hyperplasia

    Crinecerfont*: Classic Congenital Adrenal Hyperplasia Initiation of Global Registrational-Enabling Study in Adults Planned for Mid-2020 Phase IIa Pediatric Study Ongoing Congenital Adrenal Hyperplasia Crinecerfont Rare genetic disorder caused by enzyme ▪ Potent, selective, orally-active, non-peptide

  17. Slide 17: Expanding Reach: Innovative Partners with Novel Science to Address Unmet Medical Need

    Expanding Reach: Innovative Partners with Novel Science to Address Unmet Medical Need Gene Therapy Precision Medicine Opportunity to Expand Footprint into Key Areas of Establish Strong Presence to Address Unmet Medical Neuroscience with Novel Modalities Needs in Epilepsy and Other Neurological Disor

  18. Slide 18: NBIb-1817: Gene Therapy for Parkinson's Disease

    NBIb-1817*: Gene Therapy for Parkinson’s Disease Planning to Start 2nd Registrational Study in 2020 Moderate to Advanced PD NBIb-1817† One million patients with PD in the U.S., with ▪ One-time treatment restores AADC enzyme activity moderate to advanced stages of PD typically and enhance the convers

  19. Slide 19: NBI-921352: Selective NaV1.6 Inhibitor for Rare Pediatric Epilepsy

    NBI-921352*: Selective NaV1.6 Inhibitor for Rare Pediatric Epilepsy Initiation of Pediatric SCN8A-DEE† Clinical Program in 2H 2020 SCN8A-DEE NBI-921352‡ Rare form of early-onset epilepsy with ▪ First potent and selective inhibitor to precisely target occurrence of seizures beginning in the first the

  20. Slide 20: Our Vision for the Future

    BIOSCIENCES Our Vision fomihe Future _ * = *

  21. Slide 21: Transformation into Fully Integrated Neuroscience-Focused Company

    Transformation into Fully Integrated Neuroscience- Focused Company: Well-Positioned for Sustained Growth Strong Proven R&D Strategic Solid Financial Commercial with Strong Partnerships Position to Capabilities Multi-stage Invest Pipeline INGREZZA Three Approved Blockbuster Medicines in Potential; Fo

  22. Slide 22: GAAP to Non-GAAP Reconciliations

    GAAP to Non-GAAP Reconciliations neurocrine.com

  23. Slide 23: Q4 2019 Earnings Presentation

    Q4 2019 Earnings Presentation 23

  24. Slide 24: Q4 2019 Earnings Presentation

    Q4 2019 Earnings Presentation 24

  25. Slide 25: Q4 2019 Earnings Presentation

    Q4 2019 Earnings Presentation 25

  26. Slide 26: Advancing Life-Changing Discoveries in Neuroscience

    Advancing Life-Changing Discoveries in Neuroscience Q4 2019 / Year-End February 4, 2020 NASDAQ: NBIX neurocrine.com

Neurocrine Biosciences — Q4 2019 Earnings Presentation on 6ix